RÉSUMÉ
BACKGROUND: High levels of catecholamines are cardiotoxic and associated with stress-induced cardiomyopathies. Using a septic shock model that reproduces the reversible cardiomyopathy seen over 10 days associated with human septic shock, we investigated the effects of catecholamines on microcirculatory perfusion and cardiac dysfunction. METHODS AND RESULTS: Purpose-bred beagles received intrabronchial Staphylococcus aureus (n=30) or saline (n=6). The septic animals were than randomized to epinephrine (1 µg/kg per minute, n=15) or saline (n=15) infusions from 4 to 44 hours. Serial cardiac magnetic resonance imaging, catecholamine levels, and troponins were collected over 92 hours. Serial adenosine-stress perfusion cardiac magnetic resonance imaging was performed on septic animals randomized to receive saline (n=8 out of 15) or epinephrine (n=8 out of 15). High-dose sedation was given to suppress endogenous catecholamine release. Despite catecholamine levels largely remaining within the normal range throughout, by 48 hours, septic animals receiving saline versus nonseptic animals still developed significant worsening of left ventricular ejection fraction, circumferential strain, and ventricular-aortic coupling. In septic animals that received epinephrine versus saline infusions, plasma epinephrine levels increased 800-fold, but epinephrine produced no significant further worsening of left ventricular ejection fraction, circumferential strain, or ventricular-aortic coupling. Septic animals receiving saline had a significant increase in microcirculatory reserve without troponin elevations. Septic animals receiving epinephrine had decreased edema, blunted microcirculatory perfusion, and elevated troponin levels that persisted for hours after the epinephrine infusion stopped. CONCLUSIONS: Cardiac dysfunction during sepsis is not primarily due to elevated endogenous or exogenous catecholamines nor due to decreased microvascular perfusion-induced ischemia. However, epinephrine itself has potentially harmful long-lasting ischemic effects during sepsis including impaired cardiac microvascular perfusion that persists after stopping the infusion.
Sujet(s)
Cardiomyopathies , Modèles animaux de maladie humaine , Épinéphrine , Microcirculation , Choc septique , Animaux , Chiens , Choc septique/physiopathologie , Choc septique/complications , Choc septique/sang , Épinéphrine/sang , Microcirculation/effets des médicaments et des substances chimiques , Cardiomyopathies/physiopathologie , Cardiomyopathies/sang , Cardiomyopathies/étiologie , Débit systolique/effets des médicaments et des substances chimiques , Circulation coronarienne/effets des médicaments et des substances chimiques , Ischémie myocardique/physiopathologie , Ischémie myocardique/sang , Ischémie myocardique/complications , Fonction ventriculaire gauche/effets des médicaments et des substances chimiques , Catécholamines/sang , Troponine/sang , Infections à staphylocoques/microbiologie , Infections à staphylocoques/complications , Infections à staphylocoques/physiopathologie , Facteurs temps , Imagerie de perfusion myocardique/méthodes , Imagerie par résonance magnétiqueRÉSUMÉ
Despite the presence of various signs of cardiac amyloidosis ("red flags"), the introduction into routine practice of new non-invasive diagnostic methods (Speckle Tracking technology using echocardiography, myocardial scintigraphy with technetium pyrophosphate, genetic testing, screening for free light chains of immunoglobulins to exclude AL-amyloidosis), which have high specificity and sensitivity, transthyretinic (ATTR) cardiomyopathy is still a difficult to diagnose disease, especially in the early stages when treatment is most effective. The article presents a clinical case of ATTR-amyloidosis with predominant heart damage, manifested by severe diastolic heart failure resistant to treatment. The timing, from the moment of the first episode of decompensation of heart failure to death, is 4 months, which confirms the rapid progression of severe biventricular dysfunction of the heart. Despite the presence of cardiac and extracardial "red flags" of ATTR-amyloidosis in the patient, the diagnosis was established at autopsy. The paper analyzes possible errors of early diagnosis at the outpatient and inpatient stages of patient management.
Sujet(s)
Évolution de la maladie , Défaillance cardiaque , Humains , Défaillance cardiaque/étiologie , Défaillance cardiaque/diagnostic , Mâle , Issue fatale , Échocardiographie/méthodes , Neuropathies amyloïdes familiales/diagnostic , Neuropathies amyloïdes familiales/complications , Neuropathies amyloïdes familiales/physiopathologie , Adulte d'âge moyen , Cardiomyopathies/diagnostic , Cardiomyopathies/étiologie , Cardiomyopathies/physiopathologieRÉSUMÉ
ABSTRACT: Sepsis is characterized as a systemic inflammatory response syndrome resulting from infection, leading to the development of multiple organ dysfunction syndrome. Sepsis-induced cardiomyopathy (SICM) is a frequently encountered condition in clinical settings. Mesenchymal stem cells (MSCs) possess inherent immunomodulatory and anti-inflammatory attributes, rendering them a promising therapeutic approach to reestablish the equilibrium between anti-inflammatory and proinflammatory systems in septic patients. Consequently, MSCs are frequently employed in clinical investigations. In this study, the author established a mouse SICM model through cecal ligation and puncture and administered MSCs through the tail vein. Following successful modeling, the myocardial function and histopathological changes were detected by echocardiography, hematoxylin-eosin staining, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, enzyme-linked immunosorbent assay,, and other experiments. As a result, MSCs demonstrated the ability to enhance myocardial function, promote cardiac tissue repair, suppress inflammatory response, reduce levels of myocardial injury markers, and mitigate oxidative stress. In addition, transcriptome and proteome analyses were conducted. Through differential expression analysis, functional enrichment analysis, and multiomics association analysis, it was revealed that the transcriptional factors nuclear receptor subfamily 1 (NR1D2) and target gene lipocalin 2 (LCN2) played key roles in mediating the effects of MSCs on SICM. JASPAR website and ChIP-qPCR experiment were used to predict and confirm the targeting relationship between them. Subsequent cell coculture experiments and a series of experiments confirmed that MSCs attenuated cardiomyocyte injury by downregulating the expression of NR1D2 and its downstream target gene LCN2. In conclusion, MSCs alleviate mice SICM through inhibiting NR1D2/LCN2 pathway.
Sujet(s)
Cardiomyopathies , Modèles animaux de maladie humaine , Lipocaline-2 , Transplantation de cellules souches mésenchymateuses , Cellules souches mésenchymateuses , Souris de lignée C57BL , Sepsie , Transduction du signal , Animaux , Sepsie/complications , Sepsie/métabolisme , Cardiomyopathies/métabolisme , Cardiomyopathies/anatomopathologie , Cardiomyopathies/étiologie , Cardiomyopathies/physiopathologie , Cardiomyopathies/thérapie , Cellules souches mésenchymateuses/métabolisme , Mâle , Lipocaline-2/métabolisme , Lipocaline-2/génétique , Myocytes cardiaques/métabolisme , Myocytes cardiaques/anatomopathologie , Cellules cultivées , Stress oxydatif , Fonction ventriculaire gauche , Souris , ApoptoseRÉSUMÉ
Background: Myocardial inflammation and apoptosis induced by cirrhosis are among the primary mechanisms of cirrhotic cardiomyopathy. CD73, a common extracellular nucleotidase also known as 5'-nucleotidase, is associated with the progression of inflammation and immunity in multiple organs. However, the mechanism by which CD73 contributes to myocardial inflammation and apoptosis in cirrhosis remains unclear. Methods: In this study, a cirrhotic cardiomyopathy model in mice was established by bile duct ligation. Myocardial-specific overexpression of CD73 was achieved by tail vein injection of AAV9 (adeno-associated virus)-cTNT-NT5E-mCherry, and cardiac function in mice was assessed using echocardiography. Myocardial inflammation infiltration and apoptosis were evaluated through pathological observation and ELISA assays. The expression of CD73, A2AR, apoptotic markers, and proteins related to the NF-κB pathway in myocardial tissue were measured. Results: In the myocardial tissue of the cirrhotic cardiomyopathy mouse model, the expression of CD73 and A2AR increased. Overexpression of CD73 in the myocardium via AAV9 injection and stimulation of A2AR with CGS 21680 inhibited myocardial inflammation and cardiomyocyte apoptosis induced by cirrhosis. Additionally, overexpression of CD73 suppressed the activation of the NF-κB pathway by upregulating the expression of the adenosine receptor A2A. Conclusion: Our study reveals that the CD73/A2AR signaling axis mitigates myocardial inflammation and apoptosis induced by cirrhosis through negative feedback regulation of the NF-κB pathway.
Sujet(s)
5'-Nucleotidase , Cardiomyopathies , Cirrhose du foie , Récepteur A2A à l'adénosine , Transduction du signal , Animaux , Mâle , Souris , 5'-Nucleotidase/métabolisme , Apoptose , Cardiomyopathies/métabolisme , Cardiomyopathies/étiologie , Cardiomyopathies/immunologie , Modèles animaux de maladie humaine , Rétrocontrôle physiologique , Protéines liées au GPI , Cirrhose du foie/immunologie , Cirrhose du foie/métabolisme , Souris de lignée C57BL , Facteur de transcription NF-kappa B/métabolisme , Récepteur A2A à l'adénosine/métabolismeRÉSUMÉ
BACKGROUND: The adverse effects of a Western diet on obesity and diabetes among reproductive-aged women pose a significant threat to the cardiovascular health of their offspring. Given the crucial role of glutathione metabolism and glutathione-related antioxidant defense systems in cardiovascular diseases through scavenging ROS and maintaining redox homeostasis, further exploration of their specific influence is imperative to develop therapeutic strategies for cardiomyopathy induced by a maternal Western diet. METHODS: We developed a prenatal maternal Western diet exposure model in C57/B6 mice to investigate cardiac morphology and function through histological analysis and echocardiography. RNA sequencing and analysis were utilized to elucidate the mechanisms underlying the impact of a maternal Western diet and N-acetylcysteine treatment on cardiomyopathy. Additionally, ELISAs, transmission electron microscopy, and flow cytometry were employed to assess the antioxidant defense system and mitochondrial ROS levels in progenitor cardiomyocytes. RESULTS: N-acetylcysteine significantly mitigated cardiomyocyte hypertrophy, myocardial interstitial fibrosis, collagen type I accumulation, and left ventricular remodeling induced by a maternal Western diet, particularly in male offspring. Furthermore, N-acetylcysteine reversed the increase in apoptosis and the increase in the ß/α-MyHC ratio in the myocardium of offspring that results from a maternal Western diet. RNA sequencing and GSEA revealed that the beneficial effects of N-acetylcysteine were linked to its ability to modulate oxidative phosphorylation pathways. Additionally, N-acetylcysteine treatment during pregnancy can markedly elevate glutathione levels, augment glutathione peroxidase (GPx) activity, and mitigate the accumulation of mitochondrial ROS caused by a maternal Western diet. CONCLUSIONS: N-acetylcysteine mitigated cardiomyopathy induced by a maternal Western diet by bolstering glutathione synthesis and enhancing GPx activity, thereby scavenging mitochondrial ROS and modulating oxidative phosphorylation pathways.
Sujet(s)
Acétylcystéine , Cardiomyopathies , Régime occidental , Glutathion , Souris de lignée C57BL , Animaux , Femelle , Glutathion/métabolisme , Cardiomyopathies/étiologie , Cardiomyopathies/métabolisme , Grossesse , Souris , Acétylcystéine/pharmacologie , Régime occidental/effets indésirables , Mâle , Espèces réactives de l'oxygène/métabolisme , Myocytes cardiaques/métabolisme , Myocytes cardiaques/effets des médicaments et des substances chimiques , Phénomènes physiologiques nutritionnels maternels , Antioxydants/pharmacologie , Modèles animaux de maladie humaine , Effets différés de l'exposition prénatale à des facteurs de risque , Myocarde/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiquesRÉSUMÉ
OBJECTIVE: To describe the epidemiological, clinical, paraclinical, therapeutic and evolutionary characteristics of of peripartum cardiomyopathy (PPCM) in the internal medicine department of the Zinder National Hospital (ZNH). METHODS: This was a descriptive cross-sectional study carried out from 2018 to 2022 at the ZNH Department of Internal Medicine. Included were all patients admitted for PPCM who met National Heart Blood and Lung Institute criteria. The data collected was analyzed using Excel and EPI INFO v7. RESULTS: We had collected 100 cases of PPCM out of a total of 8706 hospitalized patients, i.e. a hospital prevalence of 1.14%. The mean age of the patients was 27.9 years ± 7.4 [17-45]. The majority of patients were from underprivileged social strata (n=64). The risk factors for PMPC found were essentially hot bath (n=66), home birth (n=40), natron porridge (n=35) and multiparity (n=57). Cardiac symptomatology appeared postpartum in 56% of patients. Dyspnea was the main symptom in 98% of cases. The physical signs were dominated by the functional systolic murmur (66%). Three quarters (75%) of the patients had congestive heart failure. Electrocardiographic signs were dominated by left ventricular hypertrophy (n=65). Cardiomegaly was present in 94% of patients. Left ventricular ejection fraction was altered in all patients. Impaired renal function was found in 31% of patients. Management was based on a low-sodium diet tripod, diuretics and converting enzyme inhibitors. Two cases of death were recorded. CONCLUSION: PPCM is common in the Zinder region. It affects young women with several risk factors and is revealed by signs of congestive heart failure. For a better understanding of this still poorly elucidated condition, it is necessary to pursue research efforts.
Sujet(s)
Cardiomyopathies , Période de péripartum , Complications cardiovasculaires de la grossesse , Humains , Femelle , Adulte , Études transversales , Grossesse , Cardiomyopathies/épidémiologie , Cardiomyopathies/diagnostic , Cardiomyopathies/étiologie , Jeune adulte , Complications cardiovasculaires de la grossesse/épidémiologie , Complications cardiovasculaires de la grossesse/diagnostic , Adulte d'âge moyen , Adolescent , Niger/épidémiologie , Facteurs de risque , Prévalence , Troubles du postpartum/épidémiologie , Troubles du postpartum/diagnostic , Troubles du postpartum/étiologie , Ressources en santé/statistiques et données numériquesRÉSUMÉ
Objective: To investigate the value of myocardium scar area in predicting adverse cardiovascular events (MACEs) after coronary artery bypass grafting (CABG) in patients with ischemic cardiomyopathy (ICM). Methods: The first part of this study was a retrospective study. Patients diagnosed with ICM and undergoing CABG surgery at Beijing Anzhen Hospital, Capital Medical University from January 2017 to December 2022 were enrolled as the discovery cohort. All patients underwent cardiac magnetic resonance-late gadolinium enhancement (CMR-LGE) before surgery. According to the occurrence of postoperative MACEs, the patients were divided into MACEs group and MACEs-free group. Preoperative clinical and imaging data, intraoperative and postoperative data were collected and compared between the two groups. The primary endpoint was postoperative MACEs. Univariate and multifactor regression analyses were used to analyze the risk factors for MACEs. Receiver operating characteristic (ROC) curves were constructed to evaluate the predictive efficacy and optimal cut-off value of myocardial scar area for endpoint events. The second part of this study was a prospective study. Patients with ICM who received CABG at Beijing Anzhen Hospital, Capital Medical University from January 2023 to June 2023 were enrolled as a validation cohort, and were divided into MACEs group and MACEs-free group according to whether MACEs occurred after surgery. Preoperative clinical and imaging data, intraoperative and postoperative data were collected and compared between the two groups. Verify the reliability of the cut-off value obtained by ROC curve in the validation cohort. Results: A total of 120 patients with ICM (30 patients in MACEs group and 90 patients in MACEs-free group), aged (61.6±8.7) years, including 93 males, were included in the discovery cohort. A total of 22 ICM patients (5 patients in MACEs group and 17 patients in MACEs-free group), aged (59.5±8.2) years, including 18 males, were included in the validation cohort. Multivariate Cox regression showed that myocardial scar area (HR=1.258, 95%CI 1.096-1.444, P=0.001) was an independent risk factor for the primary endpoint event. The area under ROC curve of myocardial scar area for predicting postoperative MACEs was 0.90 (95%CI 0.83-0.95), and myocardial scar area≥36.0% was the optimal cut-off value for predicting postoperative MACEs, and its sensitivity, specificity and accuracy were 96.7%, 72.2% and 78.3%, respectively. In the validation cohort, the sensitivity, specificity and accuracy of myocardial scar area in predicting postoperative MACEs in patients with ICM after CABG were 80.0%, 82.4% and 81.8%, respectively. Conclusion: Myocardial scar area is an independent risk factor for MACEs after CABG in patients with ICM, and myocardial scar area≥36.0% is the optimal cut-off value for predicting MACEs after CABG. Myocardial scar area can help to identify patients at high risk of surgery and provide a basis for risk stratification of patients.
Sujet(s)
Cardiomyopathies , Cicatrice , Pontage aortocoronarien , Ischémie myocardique , Humains , Pontage aortocoronarien/effets indésirables , Pontage aortocoronarien/méthodes , Études rétrospectives , Ischémie myocardique/étiologie , Cicatrice/étiologie , Cardiomyopathies/étiologie , Facteurs de risque , Femelle , Mâle , Études prospectives , Complications postopératoires/étiologie , Courbe ROC , Adulte d'âge moyen , Myocarde/anatomopathologieRÉSUMÉ
Arrhythmogenic cardiomyopathy (ACM) is a familial heart disease characterized by cardiac dysfunction, arrhythmias, and myocardial inflammation. Exercise and stress can influence the disease's progression. Thus, an investigation of whether a high-fat diet (HFD) contributes to ACM pathogenesis is warranted. In a robust ACM mouse model, 8-week-old Desmoglein-2 mutant (Dsg2mut/mut) mice were fed either an HFD or rodent chow for 8 weeks. Chow-fed wildtype (WT) mice served as controls. Echo- and electrocardiography images pre- and post-dietary intervention were obtained, and the lipid burden, inflammatory markers, and myocardial fibrosis were assessed at the study endpoint. HFD-fed Dsg2mut/mut mice showed numerous P-wave perturbations, reduced R-amplitude, left ventricle (LV) remodeling, and reduced ejection fraction (%LVEF). Notable elevations in plasma high-density lipoprotein (HDL) were observed, which correlated with the %LVEF. The myocardial inflammatory adipokines, adiponectin (AdipoQ) and fibroblast growth factor-1, were substantially elevated in HFD-fed Dsg2mut/mut mice, albeit no compounding effect was observed in cardiac fibrosis. The HFD not only potentiated cardiac dysfunction but additionally promoted adverse cardiac remodeling. Further investigation is warranted, particularly given elevated AdipoQ levels and the positive correlation of HDL with the %LVEF, which may suggest a protective effect. Altogether, the HFD worsened some, but not all, disease phenotypes in Dsg2mut/mut mice. Notwithstanding, diet may be a modifiable environmental factor in ACM disease progression.
Sujet(s)
Alimentation riche en graisse , Animaux , Alimentation riche en graisse/effets indésirables , Souris , Modèles animaux de maladie humaine , Myocarde/anatomopathologie , Myocarde/métabolisme , Fibrose , Mâle , Remodelage ventriculaire , Desmogléine-2/génétique , Myocardite/étiologie , Myocardite/physiopathologie , Souris de lignée C57BL , Dysplasie ventriculaire droite arythmogène/étiologie , Dysplasie ventriculaire droite arythmogène/physiopathologie , Adiponectine/sang , Inflammation , Cardiomyopathies/étiologie , Cardiomyopathies/physiopathologieRÉSUMÉ
BACKGROUND: We aim to provide a comprehensive review of the current state of knowledge of myocardial viability assessment in patients undergoing coronary artery bypass grafting (CABG), with a focus on the clinical markers of viability for each imaging modality. We also compare mortality between patients with viable myocardium and those without viability who undergo CABG. METHODS: A systematic database search with meta-analysis was conducted of comparative original articles (both observations and randomized controlled studies) of patients undergoing CABG with either viable or nonviable myocardium, in EMBASE, MEDLINE, Cochrane database, and Google Scholar, from inception to 2022. Imaging modalities included were dobutamine stress echocardiography (DSE), cardiac magnetic resonance (CMR), single-photon emission computed tomography (SPECT), and positron emission tomography (PET). RESULTS: A total of 17 studies incorporating a total of 2317 patients were included. Across all imaging modalities, the relative risk of death post-CABG was reduced in patients with versus without viability (random-effects model: odds ratio: 0.42; 95% confidence interval: 0.29-0.61; p < 0.001). Imaging for myocardial viability has significant clinical implications as it can affect the accuracy of the diagnosis, guide treatment decisions, and predict patient outcomes. Generally, based on local availability and expertise, either SPECT or DSE should be considered as the first step in evaluating viability, while PET or CMR would provide further evaluation of transmurality, perfusion metabolism, and extent of scar tissue. CONCLUSION: The assessment of myocardial viability is an essential component of preoperative evaluation in patients with ischemic heart disease undergoing surgical revascularization. Careful patient selection and individualized assessment of viability remain paramount.
Sujet(s)
Pontage aortocoronarien , Ischémie myocardique , Fonction ventriculaire gauche , Humains , Cardiomyopathies/physiopathologie , Cardiomyopathies/chirurgie , Cardiomyopathies/diagnostic , Cardiomyopathies/étiologie , Pontage aortocoronarien/effets indésirables , Maladie des artères coronaires/chirurgie , Maladie des artères coronaires/physiopathologie , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/complications , Échocardiographie de stress/méthodes , Ischémie myocardique/physiopathologie , Ischémie myocardique/chirurgie , Ischémie myocardique/diagnostic , Ischémie myocardique/complications , Myocarde/anatomopathologie , Survie tissulaire , Tomographie par émission monophotonique , Dysfonction ventriculaire gauche/physiopathologie , Dysfonction ventriculaire gauche/étiologie , Fonction ventriculaire gauche/physiologieRÉSUMÉ
Preeclampsia and peripartum cardiomyopathy (PPCM) are significant obstetric problems that can arise during or after pregnancy. Both are known to be causes of maternal mortality and morbidity. Several recent studies have suggested a link between preeclampsia and the pathophysiology of PPCM. However, the common thread that connects the two has yet to be thoroughly and fully articulated. Here, we investigate the complex dynamics of preeclampsia and PPCM in this review. Our analysis focuses mainly on inflammatory and immunological responses, endothelial dysfunction as a shared pathway, and potential genetic predisposition to both diseases. To begin, we will look at how excessive inflammatory and immunological responses can lead to clinical symptoms of both illnesses, emphasizing the role of proinflammatory cytokines and immune cells in modifying vascular and tissue responses. Second, we consider endothelial dysfunction to be a crucial point at which endothelial damage and activation contribute to pathogenesis through increased vascular permeability, vascular dysfunction, and thrombus formation. Finally, we examine recent information suggesting genetic predispositions to preeclampsia and PPCM, such as genetic variants in genes involved in the management of blood pressure, the inflammatory response, and heart structural integrity. With this synergistic study, we seek to encourage more research and creative therapy solutions by emphasizing the need for an interdisciplinary approach to understanding and managing the connection between preeclampsia and PPCM.
Sujet(s)
Cardiomyopathies , Période de péripartum , Pré-éclampsie , Humains , Femelle , Pré-éclampsie/physiopathologie , Pré-éclampsie/génétique , Grossesse , Cardiomyopathies/étiologie , Cardiomyopathies/génétique , Cardiomyopathies/physiopathologie , Prédisposition génétique à une maladie , Endothélium vasculaire/physiopathologie , Complications cardiovasculaires de la grossesse/physiopathologie , Complications cardiovasculaires de la grossesse/génétiqueSujet(s)
Fibrillation auriculaire , Cardiomyopathies , Défaillance cardiaque , Humains , Fibrillation auriculaire/complications , Cardiomyopathies/physiopathologie , Cardiomyopathies/étiologie , Cardiomyopathies/complications , Défaillance cardiaque/étiologie , Défaillance cardiaque/physiopathologieSujet(s)
Fibrillation auriculaire , Cardiomyopathies , Défaillance cardiaque , Humains , Fibrillation auriculaire/complications , Fibrillation auriculaire/physiopathologie , Cardiomyopathies/physiopathologie , Cardiomyopathies/étiologie , Cardiomyopathies/complications , Défaillance cardiaque/étiologie , Défaillance cardiaque/physiopathologie , Mâle , Femelle , Sujet âgé , Adulte d'âge moyen , Facteurs de risqueRÉSUMÉ
The aim of this study is to assess the effectiveness of conventional and two additional functional markers derived from standard cardiac magnetic resonance (CMR) images in detecting the occurrence of late gadolinium enhancement (LGE) in patients with secondary cardiac amyloidosis (CA) related to multiple myeloma (MM). This study retrospectively included 32 patients with preserved ejection fraction (EF) who had MM-CA diagnosed consecutively. Conventional left ventricular (LV) function markers and two additional functional markers, namely myocardial contraction fraction (MCF) and LV long-axis strain (LAS), were obtained using commercial cardiac post-processing software. Logistic regression analyses and receiver operating characteristic (ROC) analysis were performed to evaluate the predictive performances. (1) There were no notable distinctions in clinical features between the LGE+ and LGE- groups, with the exception of a reduced systolic blood pressure in the former (105.60 ± 18.85 mmHg vs. 124.50 ± 20.95 mmHg, P = 0.022). (2) Patients with MM-CA presented with intractable heart failure with preserved ejection fraction (HFpEF). The LVEF in the LGE+ group exhibited a greater reduction (54.27%, IQR 51.59-58.39%) in comparison to the LGE- group (P < 0.05). And MM-CA patients with LGE+ had significantly higher LVMI (90.15 ± 23.69 g/m2), lower MCF (47.39%, IQR 34.28-54.90%), and the LV LAS were more severely damaged (- 9.94 ± 3.42%) than patients with LGE- (all P values < 0.05). (3) The study found that MCF exhibited a significant independent association with LGE, as indicated by an odds ratio of 0.89 (P < 0.05). The cut-off value for MCF was determined to be 64.25% with a 95% confidence interval ranging from 0.758 to 0.983. The sensitivity and specificity of this association were calculated to be 95% and 83%, respectively. MCF is a simple reproducible predict marker of LGE in MM-CA patients. It is a potentially CMR-based method that promise to reduce scan times and costs, and boost the accessibility of CMR.
Sujet(s)
Amyloïdose , Gadolinium , Myélome multiple , Contraction myocardique , Humains , Myélome multiple/imagerie diagnostique , Myélome multiple/complications , Myélome multiple/anatomopathologie , Femelle , Mâle , Sujet âgé , Adulte d'âge moyen , Amyloïdose/imagerie diagnostique , Amyloïdose/physiopathologie , Amyloïdose/anatomopathologie , Études rétrospectives , Débit systolique , Fonction ventriculaire gauche , Produits de contraste , Imagerie par résonance magnétique/méthodes , Cardiomyopathies/imagerie diagnostique , Cardiomyopathies/physiopathologie , Cardiomyopathies/étiologie , Courbe ROC , IRM dynamique/méthodesRÉSUMÉ
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease caused by mutations to the dystrophin gene, resulting in deficiency of dystrophin protein, loss of myofiber integrity in skeletal and cardiac muscle, and eventual cell death and replacement with fibrotic tissue. Pathologic cardiac manifestations occur in nearly every DMD patient, with the development of cardiomyopathy-the leading cause of death-inevitable by adulthood. As early cardiac abnormalities are difficult to detect, timely diagnosis and appropriate treatment modalities remain a challenge. There is no cure for DMD; treatment is aimed at delaying disease progression and alleviating symptoms. A comprehensive understanding of the pathophysiological mechanisms is crucial to the development of targeted treatments. While established hypotheses of underlying mechanisms include sarcolemmal weakening, upregulation of pro-inflammatory cytokines, and perturbed ion homeostasis, mitochondrial dysfunction is thought to be a potential key contributor. Several experimental compounds targeting the skeletal muscle pathology of DMD are in development, but the effects of such agents on cardiac function remain unclear. The synergistic integration of small molecule- and gene-target-based drugs with metabolic-, immune-, or ion balance-enhancing compounds into a combinatorial therapy offers potential for treating dystrophin deficiency-induced cardiomyopathy, making it crucial to understand the underlying mechanisms driving the disorder.
Sujet(s)
Cardiomyopathies , Mitochondries , Myopathie de Duchenne , Myopathie de Duchenne/complications , Myopathie de Duchenne/thérapie , Myopathie de Duchenne/anatomopathologie , Humains , Cardiomyopathies/thérapie , Cardiomyopathies/métabolisme , Cardiomyopathies/anatomopathologie , Cardiomyopathies/étiologie , Animaux , Mitochondries/métabolisme , Dystrophine/métabolisme , Dystrophine/génétique , Dystrophine/déficitSujet(s)
Amyloïdose , Sténose aortique , Remplacement valvulaire aortique par cathéter , Humains , Amyloïdose/chirurgie , Sténose aortique/chirurgie , Cardiomyopathies/chirurgie , Cardiomyopathies/étiologie , Méta-analyse comme sujet , Remplacement valvulaire aortique par cathéter/effets indésirables , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Tachycardia-induced cardiomyopathy (TIC) is a reversible cardiomyopathy with ventricular dysfunction caused by tachyarrhythmias. Notably, atrial fibrillation (AF) is the most common causal arrhythmia leading to TIC. However, the risk factors for the development of TIC due to AF remain unclear. This study aimed to identify the associated factors of TIC due to AF. METHODS: Persistent AF patients with heart rate (HR) ≥100 beats per minute who underwent initial catheter ablation were enrolled in this study. TIC was diagnosed as left ventricular ejection fraction (LVEF) < 50% during AF rhythm, which was recovered after the restoration of sinus rhythm. Non-TIC was defined as LVEF ≥ 50% despite AF rhythm. The patient backgrounds were compared between the TIC group and the non-TIC group to reveal the contributing factors of TIC. RESULTS: The TIC group comprised 57 patients, while the non-TIC group consisted of 101 patients. The TIC group was younger than the non-TIC group (median 64 vs. 70, p = 0.006). Male sex was more frequent in the TIC group than the non-TIC group (82.5% vs. 58.4%, p = 0.003). HR was higher in the TIC group than in the non-TIC group (median 130 bpm vs. 111 bpm, p < 0.001). The number of smokers was significantly higher in the TIC group than in the non-TIC group (p < 0.001). Multivariable analysis demonstrated that higher HR (odds ratio [OR]: 1.74; 95% confidence interval [CI]: 1.37-2.21; p < 0.001) and current smokers (OR: 5.27; 95% CI: 1.60-17.4; p = 0.006) were the independent factors leading to TIC. CONCLUSION: Higher HR and current smokers were independent risk factors for the development of TIC due to AF.
Sujet(s)
Fibrillation auriculaire , Cardiomyopathies , Humains , Fibrillation auriculaire/étiologie , Mâle , Femelle , Facteurs de risque , Adulte d'âge moyen , Cardiomyopathies/étiologie , Sujet âgé , Tachycardie/physiopathologie , Tachycardie/complications , Ablation par cathéterRÉSUMÉ
(1) Heart transplantation (HTX) improves the overall survival and functional status of end-stage heart failure patients with cardiomyopathies (CMPs). The majority of CMPs have genetic causes, and the overlap between CMPs and inherited myopathies is well documented. However, the long-term outcome in skeletal muscle function and possibility of an undiagnosed underlying genetic cause of both a cardiac and skeletal pathology remain unknown. (2) Thirty-nine patients were assessed using open and standardized interviews on muscle function, a quality-of-life (EuroQol EQ-5D-3L) questionnaire, and a physical examination (Medical Research Council Muscle scale). Whole-exome sequencing was completed in three stages for those with skeletal muscle weakness. (3) Seven patients (17.9%) reported new-onset muscle weakness and motor limitations. Objective muscle weakness in the upper and lower extremities was seen in four patients. In three of them, exome sequencing revealed pathogenic/likely pathogenic variants in the genes encoding nexilin, myosin heavy chain, titin, and SPG7. (4) Our findings support a positive long-term outcome of skeletal muscle function in HTX patients. However, 10% of patients showed clinical signs of myopathy due to a possible genetic cause. The integration of genetic testing and standardized neurological assessment of motor function during the peri-HTX period should be considered.
Sujet(s)
Transplantation cardiaque , Maladies neuromusculaires , Humains , Transplantation cardiaque/effets indésirables , Mâle , Femelle , Adulte d'âge moyen , Maladies neuromusculaires/génétique , Adulte , Qualité de vie , , Muscles squelettiques/anatomopathologie , Muscles squelettiques/physiopathologie , Sujet âgé , Défaillance cardiaque/génétique , Défaillance cardiaque/chirurgie , Défaillance cardiaque/étiologie , Cardiomyopathies/génétique , Cardiomyopathies/étiologie , Faiblesse musculaire/étiologie , Faiblesse musculaire/génétique , Connectine/génétiqueRÉSUMÉ
Sepsis-induced myocardial depression (SIMD), a common complication of sepsis, is one of the main causes of death in patients with sepsis. The pathogenesis of SIMD is complicated, and the process of SIMD remains incompletely understood, with no single or definitive mechanism fully elucidated. Notably, pyroptosis, as a pro-inflammatory programmed cell death, is characterized by Gasdermin-mediated formation of pores on the cell membrane, cell swelling, and cell rupture accompanied by the release of large amounts of inflammatory factors and other cellular contents. Mechanistically, pyroptosis is mainly divided into the canonical pathway mediated by caspase-1 and the non-canonical pathway mediated by caspase-4/5/11. Pyroptosis has been confirmed to participate in various inflammation-associated diseases. In recent years, more and more studies have shown that pyroptosis is also involved in the occurrence and development of SIMD. This article reviews the molecular mechanisms of pyroptosis and its research progress in SIMD, aiming to provide novel strategies and targets for the treatment of SIMD.
Sujet(s)
Pyroptose , Sepsie , Humains , Sepsie/complications , Animaux , Cardiomyopathies/étiologieRÉSUMÉ
Right ventricular pacing (RVP) is conventionally preferred in the treatment of patients with atrioventricular block. However, long-term RVP may lead to pacing-induced cardiomyopathy (PICM), characterized by new-onset or worsening ventricular functions due to dyssynchronous ventricular electrical activation, abnormal ventricular remodeling, and increased energy expenditure. Historically, biventricular pacing (BVP) and guideline-directed medical therapy were the only treatment option for PICM. Recently, conduction system pacing, including left bundle branch area pacing (LBBaP), has emerged as a physiological alternative to BVP, showing better results in electro-mechanical ventricular synchronization and hemodynamic parameters compared to BVP. We present a case involving a patient from whom the PICM was successfully recovered shortly after LBBaP.
Sujet(s)
Entraînement électrosystolique , Cardiomyopathies , Humains , Cardiomyopathies/thérapie , Cardiomyopathies/étiologie , Entraînement électrosystolique/méthodes , Entraînement électrosystolique/effets indésirables , Électrocardiographie , Mâle , Ventricules cardiaques/physiopathologieRÉSUMÉ
AIMS: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) experience reduced functional capacity. We evaluated changes in functional capacity over extensive follow-up using cardiopulmonary exercise testing (CPX). METHODS: ATTR-CM patients underwent CPX and blood testing at baseline, first [V1, 8 (6-10) months] and second follow-up (V2) at 35 (26-41) months after start of disease-specific therapy. RESULTS: We included 34 ATTR-CM patients, aged 77 (±6) years (88.2% men). CPX showed two patterns with functional capacity improvement at V1 and deterioration at V2. Peak work capacity ( P = 0.005) and peak oxygen consumption (VO 2 , P = 0.012) increased at V1 compared with baseline and decreased at V2. The ventilation to carbon dioxide relationship slope (VE/VCO 2 ) increased at V2 compared with baseline and V1 ( P = 0.044). A cut-off for peak VO 2 at 14âml/kg·min showed more events (composite of death and heart failure hospitalization): less than 14 vs. greater than 14âml/kg·min ( P â=â0.013). Cut-offs for VE/VCO 2 slope at 40 showed more events greater than 40 vs. less than 40 ( P â=â0.009). CONCLUSION: ATTR-CM patients showed an improvement and deterioration in the short-term and long-term follow-up, respectively, with a better prognosis for those with peak VO 2 above 14âml/kg·min and for a VE/VCO 2 slope below 40.